Ying Huang, Legend Biotech CEO
July 26, 2022 07:17 AM EDT
Financing

Leg­end seeks $250M af­ter pos­i­tive #AS­CO22 da­ta, but chal­lenges re­main for the J&J part­ner

Max Gelman

Senior Editor

J&J-part­nered Leg­end Biotech has had its share of both good and bad news in re­cent weeks, and ex­ecs ev­i­dent­ly be­lieve the for­mer out­weighs the lat­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times